Clinical Trials Browser

Phase 3 × Axitinib × Clear all

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 2 FDA

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 2 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT06364631 2025-01-16

CARE1

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00920816 2022-05-06

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Phase 3 Completed

492 enrolled 17 charts

Kidney Neoplasms

NCT01599754 2019-09-20

ATLAS

Phase 3 Terminated

724 enrolled 17 charts

Carcinoma, Renal Cell

NCT00678392 2019-01-09

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Phase 3 Completed

723 enrolled 15 charts

Kidney Neoplasms

NCT00471146 2012-07-16

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Phase 3 Completed

630 enrolled 13 charts

Gastrointestinal

Carcinoma, Pancreatic Ductal